Daraxonrasib offers new hope for pancreatic cancer patients in clinical trials

Pancreatic cancer remains one of the deadliest cancers with historically poor survival rates; this drug offers potential relief for thousands of affected patients.

For decades, pancreatic cancer has occupied a grim corner of medicine where hope arrives slowly and departs quickly — a disease that kills roughly 50,000 Americans each year, most of them diagnosed too late for surgery and too advanced for anything more than borrowed time. Now, a drug called daraxonrasib has emerged from the long, largely frustrated effort to disable the RAS gene mutation that drives nearly all pancreatic cancers, offering early clinical evidence compelling enough that oncologists — a community not given to easy optimism — are calling it a potential turning point. The drug's a

Daraxonrasib offers new hope for pancreatic cancer patients in clinical trials

Cobertura Relacionada

Receba o Register no seu e-mail